Life science remains a hot topic for many within real estate, with a number of new entrants looking to break into the UK market as the sector continues to mature. However, with the current funding landscape impacted by wider macro-economics, and more hesitancy from those looking to invest, it is important to stress that the fundamentals remain strong.

Join Guy Ruddle and guests, Tom Mellows, Savills head of UK science, Olivia Drew, director and portfolio manager of UK life sciences at UBS and Freddie Dear, investment manager at Monograph Capital and head of corporate development at Ascend Gene & Cell Therapies, as they discuss what’s needed to meet the sector’s growing requirements.

This podcast is for general information only and should not be considered professional advice. Savills accepts no liability or responsibility for any direct, indirect or consequential loss arising from the use of, reference to or reliance on, this podcast or its content. Savills makes no warranty as to the accuracy of the information in this podcast. This podcast, and all copyright in this podcast, is the property of Savills and it shall not be used, reproduced or quoted in whole or in part without Savills prior written consent.